0

Global Postmenopausal Osteoporosis Drugs Market 2016-2020

  • Published: May 2016
  • Pages: 60
  • SKU: IRTNTR9271
Technavio

The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

This market research study presents a detailed segmentation of the global postmenopausal osteoporosis drugs market by therapeutic class (antiresorptive medications and anabolic medications), by line of therapy (first line of therapy and second line of therapy), and by geography (the Americas, APAC, and EMEA). Leading vendors in this market are Eli Lilly, Amgen, Merck, and Novartis.

Outlook of the postmenopausal osteoporosis drugs market

Technavio’s market research analyst predicts the global postmenopausal osteoporosis drugs market to grow steadily at a CAGR of more than 4% over the forecast period. With the expected launch of promising pipeline molecules, the market for postmenopausal osteoporosis has a positive outlook in the coming years. The postmenopausal osteoporosis drugs market is characterized by the presence of promising late-stage molecules that are being developed by the major and upcoming players in this market. Some of the late-stage pipeline molecules that are envisaged to be launched during the forecast period are Tarsa Therapeutics’ TBRIA, romosozumab, Merck’ odanacatib (Phase III), and Radius Health’s abaloparatide (Phase III).

In this industry research report, the analysts have estimated factors such as the emergence of combination therapies to contribute to this market’s growth in the next four years. Anabolic and antiresorptive agents can significantly enhance bone density and strength as a combination therapy than as monotherapy. Clinical trials have been performed evaluating the effect of PTH1-34 or PTH1-84 in combination with antiresorptive drugs, including raloxifene, alendronate, and risedronate. Moreover, it has been observed that combining antiresorptive drugs with PTH or teriparatide has been successful in providing greater bone mineral density. For instance, Pfizer's Duavee is a combination of conjugated estrogens and bazedoxifene used in the treatment of postmenopausal osteoporosis with few side effects.

Segmentation by line of therapy and analysis of the postmenopausal osteoporosis drugs market

  • First line of therapy
  • Second line of therapy

During 2015, the first line of therapy segment dominated the market and accounted for more than 64% of the market share. Optimal consumption of calcium and vitamin D is recommended as the first line of therapy to prevent and treat osteoporosis. Whereas, biphosphates are considered as a baseline preventive treatment for low bone density and glucocorticoid-induced osteoporosis in postmenopausal women. The second line of therapy is given when the initial treatment fails or is not tolerated by the patient, thereby aiding in the growth prospects of this market segment over the predicted period.

Geographical segmentation and analysis of the postmenopausal osteoporosis drugs market  

  • Americas
  • APAC
  • EMEA

The Americas dominated the postmenopausal osteoporosis drugs market and accounted for nearly 46% of the market share during 2015. The US was the largest revenue contributor to the region because of the increased prevalence of the disease. Factors such as the increasing patient population and easy availability of drugs will contribute to the growth of this market in the region.

Competitive landscape and key vendors

The global postmenopausal osteoporosis drugs market is highly competitive due to the presence of several international and regional vendors. The market is open to new players and has a lot of opportunities for growth.  The competitive environment is expected to increase in due to the product extensions, new products, and new applications of the products and services provided. 

Key vendors in this market are –

  • Eli Lilly
  • Amgen
  • Merck
  • Novartis

Other prominent vendors analyzed in this market research report are Allergan, Amgen Astellas Biopharm K.K., Deltanoid Pharmaceuticals, Noven, Novo Nordisk, Osteologix, Pfizer, PhytoHealth Corporation, Radius Health, Tarsa Therapeutics, UCB, Uni-Bio Science Group Limited, Upsher-Smith Laboratories, Watson Pharmaceuticals, and Zosano Pharma Inc.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020?
  • What are the key factors driving the global postmenopausal osteoporosis drugs market?
  • What are the key market trends impacting the growth of the global postmenopausal osteoporosis drugs market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global postmenopausal osteoporosis drugs market?
  • What are the market opportunities and threats faced by the vendors in the global postmenopausal osteoporosis drugs market?
  • Trending factors influencing the market shares of the Americas, APAC, and EMEA.
  • What are the key outcomes of the five forces analysis of global postmenopausal osteoporosis drugs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

Read More Read Less

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of  the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding postmenopausal osteoporosis
  • Epidemiology and demography
  • Risk factors
  • Symptoms
  • Diagnosis
  • Treatment

PART 06: Key buying criteria

PART 07: Pipeline scenario

  • TBRIA
  • Romosozumab (AMG785)
  • Odanacatib (MK-0822)
  • Abaloparatide SC/Abaloparatide transdermal patch
  • PHN-031 (PH3)
  • NB S101
  • Teriparatide ZP Patch (ZP-PTH)
  • Blosozumab (LY2541546)

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by therapeutic class

  • Antiresorptive medications
  • Anabolic medications

PART 10: Market segmentation by line of therapy

PART 11: Geographical segmentation

  • Global postmenopausal osteoporosis drugs market by geographical segmentation 2015-2020
  • Postmenopausal osteoporosis drugs market in Americas
  • Postmenopausal osteoporosis drugs market in EMEA
  • Postmenopausal osteoporosis drugs market in APAC

PART 12: Market drivers

  • Increase in older population
  • Growing prevalence of postmenopausal osteoporosis
  • Expected launch of promising pipeline molecules
  • High unmet medical needs

PART 13: Impact of drivers

PART 14: Market challenges

  • Multiple patent expiries
  • Low diagnosis rate
  • Nonadherence to treatment regimen
  • Drug reimbursement issues

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Awareness programs and initiatives
  • Emergence of novel agents
  • Emergence of combination therapies

PART 17: Vendor landscape

  • Competitive scenario
  • Market analysis 2015
  • Eli Lilly
  • Amgen
  • Merck
  • Novartis
  • Other prominent vendors

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

TechnavioINFORMATION SOURCES

Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases
Technavio

TechnavioDATA ANALYSIS

Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts
Technavio

TechnavioREPORT WRITING

Qualitative

  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis

Quantitative

  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
Safe and Secure SSL Encrypted
Technavio

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase
Technavio
Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>